Clinical Trials Logo

Clinical Trial Summary

Primary Objective of this study: To assess experimental heat pain responses (pain intensity, pain unpleasantness, pain catastrophizing, emotional reactivity) in migraineurs vs. healthy controls.

The current tools of migraine pain measurement are inadequate to distinguish the overall burden of suffering, as there is an over reliance on a single numerical pain score to represent the entire pain experience. Measuring and targeting the affective component, in addition to the sensory component of pain, may capture this discrepancy in disease burden. The affective component of migraine pain may be just as important as the sensory component to target and measure since it significantly impacts outcomes, disability, and has therapeutic treatment implications.

Quantitative sensory testing (QST) is a robust lab paradigm (not a clinical experience) that delivers one painful noxious thermal stimuli and asks for simultaneous pain intensity and pain unpleasantness scores. By using this in the research, investigators will be able to differentiate the sensory (pain quality—what the pain feels like) from the affective (how awful/unpleasant the pain feels) components of experimental pain in normal controls vs. migrainuers.

No previous studies have evaluated differences in experimental pain intensity vs. pain unpleasantness in migraineurs vs. controls. As migraine pain uniquely involves many altered sensory phenomenon (e.g., photophobia, phonophobia), it cannot be assumed that responses to experimental pain in migraine will be the same as other clinical pain syndromes. Further, different clinical pain syndromes have distinct responses to pain intensity vs. pain unpleasantness.


Clinical Trial Description

Investigators will conduct a cross-sectional study in migraineurs (interictally, i.e., between migraine attacks) and healthy controls to compare responses to experimental heat pain intensity and unpleasantness and correlate these results to differences in emotional reactivity and pain catastrophizing. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02748577
Study type Interventional
Source Wake Forest University Health Sciences
Contact
Status Completed
Phase N/A
Start date August 24, 2016
Completion date July 16, 2019

See also
  Status Clinical Trial Phase
Completed NCT01547494 - A Nutritional Intervention for Migraines N/A
Recruiting NCT06022848 - Quantitative Sensory Testing and Occipital Nerve Stimulator N/A
Completed NCT01813669 - Integrative Coping Group for Children N/A
Completed NCT01699009 - A Nutritional Intervention for Migraines-2 N/A
Completed NCT03844412 - Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments Phase 2
Completed NCT01431326 - Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Terminated NCT04201080 - A Trial to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous TRV250 Phase 1
Completed NCT00727974 - Genetic Analysis of Children With Cyclic Vomiting Syndrome (CVS) and Migraines
Completed NCT00700128 - Prevention of Menstrual Migraines: Using Frovatriptan or Placebo During Hormone Free Intervals N/A
Completed NCT00195754 - A Phase III Open-Label, Multi-Center, Long-Term Extension Study of Depakote ER in Subjects Who Either Completed or Prematurely Discontinued Due to Ineffectiveness From Study M02-488. Phase 3
Completed NCT01807234 - Comparison of Ketorolac Nasal Spray to Sumatriptan Nasal Spray and Placebo for Acute Treatment of Migraine Phase 4
Completed NCT00753493 - Pharmacokinetics and Safety of Intravenous Topiramate in Adult Patients Phase 1
Completed NCT00483704 - Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031) Phase 3
Completed NCT01337596 - A Study of LY2951742 in Healthy Volunteers Phase 1